Baseline characteristics of patients included in each analysis.

First analysis: leukocytes at 6 months, excluding relapses at 6 months; Second analysis: leukocytes at 6 months, including relapses at 6 months, two-step algorithms. Combination treatment: within this selected cohort, it included melarsoprol-eflornithine, nifurtimox-eflornithine and melarsoprol-nifurtimox combinations. Coma score: Glasgow Coma Scale assessing the level of consciousness. Interpretation: 3–8 = severe impairment; 9–12 = moderate impairment; 13–14 = mild impairment; 15 = normal [13]; Karnofsky index [14].